All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

Mechanisms of action of ibrutinib, ruxolitinib, and belumosudil, and their role in cGvHD treatment

The GvHD Hub was pleased to speak with Robert Zeiser, Medical Center – University of Freiburg, Freiburg, DE, about the mechanisms of action of ibrutinib, ruxolitinib, and belumosudil, and their role in chronic graft-versus-host disease (cGvHD) treatment.

Mechanisms of action of ibrutinib, ruxolitinib, and belumosudil, and their role in cGvHD treatment

Zeiser begins by providing an overview of cGvHD and its implications for patients. This is followed by a discussion on three recently approved drugs, ibrutinib, ruxolitinib, and belumosudil, including their mechanisms of action in relation to cGvHD (Figure 1). Finally, Zeiser summarizes the clinical activity and recent trials investigating these drugs.

Figure 1. The mechanisms of action of ibrutinib, belumosudil, and ruxolitinib, and their treatment effects in cGvHD*

BCR, B-cell receptor; cGvHD, chronic graft-versus-host disease; ECM, extracellular matrix; IFN, interferon; IL, interleukin; TCR, T-cell receptor; Th17 cells, T helper 17 cells; T reg cells, regulatory T cells.
*Adapted from Zeiser et al.1

 

  1. Zeiser R, Lee S. Three FDA-approved therapies for chronic GVHD. 2022;139(11):1642-1645. DOI: 10.1182/blood.2021014448